Commercial products achieve strong revenue and market share performance VyleesiTM (bremelanotide injection) launched nationally in September Committed to work with the FDA to keep Makena available for at-risk pregnant women Conference call scheduled for 8:00 a.m. ET today   WALTHAM, MA (November 1, 2019) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results… More

Company to Comment During Third Quarter Financial Results Conference Call on  Friday, November 1, 2019, at 8:00 a.m. ET   WALTHAM, Mass., October 29, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced  the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee met to better understand and interpret the PROLONG (Progestin’s… More

WALTHAM, Mass. October 25, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the results of PROLONG (Progestin’s Role in Optimizing Neonatal Gestation) were published online in the American Journal of Perinatology. PROLONG was a randomized, double-blind, placebo-controlled clinical trial evaluating 17-OPHC (17-α-hydroxyprogesterone caproate or Makena®) in patients with a history of a prior spontaneous singleton preterm… More

The RECONNECT Studies Demonstrated a Clinically Meaningful and Statistically Significant Improvement in the Co-Primary Endpoints of Desire and Associated Distress  WALTHAM, Mass. October 11, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and its voluntary open-label one year extension studies were published in… More

WALTHAM, Mass., September 25, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, October 3, 2019. Ted Myles, chief financial officer, will participate in a fireside chat at 10:40 a.m. ET. A live audio webcast will be accessible through the Investors section of the… More

Details Caligan Partners’ Reckless Business Ideas and Inexperienced Director Nominees   Urges Shareholders to Sign and Return AMAG’s GREEN Consent Revocation Card   WALTHAM, Mass., Sept. 23, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG” or the “Company”) today announced that it filed a definitive consent revocation statement with the U.S. Securities and Exchange Commission… More

Urges Shareholders Take No Action On Caligan Consent Solicitation   WALTHAM, Mass., Sept. 12, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its shareholders.   AMAG’s Board urges all AMAG shareholders to refrain from taking any action (including returning any consent card sent… More

WALTHAM, Mass., September 5, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Bill Heiden, president and chief executive officer, and Ted Myles, chief financial officer, will participate in a fireside chat at 5:15 p.m. EDT.   A live audio webcast will be accessible… More

WALTHAM, Mass., Sept. 4, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today responded to the preliminary consent solicitation filed by Caligan Partners (“Caligan”) with the following statement:   “AMAG regularly engages with shareholders on a range of topics and values their constructive input and is committed to act in the best interest… More

The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients   WALTHAM, Mass. August 27, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is… More